Minimally invasive versus open liver resections for hepatocellular carcinoma in patients with metabolic syndrome Journal Article


Authors: Berardi, G.; Ivanics, T.; Sapisochin, G.; Ratti, F.; Sposito, C.; Nebbia, M.; D'Souza, D. M.; Pascual, F.; Tohme, S.; D'Amico, F. E.; Alessandris, R.; Panetta, V.; Simonelli, I.; Del Basso, C.; Russolillo, N.; Fiorentini, G.; Serenari, M.; Rotellar, F.; Zimitti, G.; Famularo, S.; Hoffman, D.; Onkendi, E.; Lopez-Ben, S.; Caula, C.; Rompianesi, G.; Chopra, A.; Abu Hilal, M.; Torzilli, G.; Corvera, C.; Alseidi, A.; Helton, S.; Troisi, R. I.; Simo, K.; Conrad, C.; Cescon, M.; Cleary, S.; Kwon, C. H. D.; Ferrero, A.; Ettorre, G. M.; Cillo, U.; Geller, D.; Cherqui, D.; Serrano, P. E.; Ferrone, C.; Mazzaferro, V.; Aldrighetti, L.; Kingham, T. P.
Article Title: Minimally invasive versus open liver resections for hepatocellular carcinoma in patients with metabolic syndrome
Abstract: OBJECTIVE: To compare minimally invasive (MILR) and open liver resections (OLRs) for hepatocellular carcinoma (HCC) in patients with metabolic syndrome (MS). BACKGROUND: Liver resections for HCC on MS are associated with high perioperative morbidity and mortality. No data on the minimally invasive approach in this setting exist. MATERIAL AND METHODS: A multicenter study involving 24 institutions was conducted. Propensity scores were calculated, and inverse probability weighting was used to weight comparisons. Short-term and long-term outcomes were investigated. RESULTS: A total of 996 patients were included: 580 in OLR and 416 in MILR. After weighing, groups were well matched. Blood loss was similar between groups (OLR 275.9±3.1 vs MILR 226±4.0, P =0.146). There were no significant differences in 90-day morbidity (38.9% vs 31.9% OLRs and MILRs, P =0.08) and mortality (2.4% vs 2.2% OLRs and MILRs, P =0.84). MILRs were associated with lower rates of major complications (9.3% vs 15.3%, P =0.015), posthepatectomy liver failure (0.6% vs 4.3%, P =0.008), and bile leaks (2.2% vs 6.4%, P =0.003); ascites was significantly lower at postoperative day 1 (2.7% vs 8.1%, P =0.002) and day 3 (3.1% vs 11.4%, P <0.001); hospital stay was significantly shorter (5.8±1.9 vs 7.5±1.7, P <0.001). There was no significant difference in overall survival and disease-free survival. CONCLUSIONS: MILR for HCC on MS is associated with equivalent perioperative and oncological outcomes to OLRs. Fewer major complications, posthepatectomy liver failures, ascites, and bile leaks can be obtained, with a shorter hospital stay. The combination of lower short-term severe morbidity and equivalent oncologic outcomes favor MILR for MS when feasible. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Journal Title: Annals of Surgery
Volume: 278
Issue: 5
ISSN: 0003-4932
Publisher: Lippincott Williams & Wilkins  
Date Published: 2023-11-01
Start Page: e1041
End Page: e1047
Language: English
DOI: 10.1097/sla.0000000000005861
PUBMED: 36994755
PROVIDER: scopus
PMCID: PMC11218006
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. T Peter Kingham
    612 Kingham